Top Page
Aceso Life Science Group Limited
(0474)
Aceso Life Science Group Limited (0474) vs. iShares MSCI Hong Kong ETF (EWH)
Aceso Life Science Group Limited Business Overview & Revenue Model
Aceso Life Science Group Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.00M | 195.00M | 11.00M | 312.00M | 315.00M | 346.00M |
| Gross Profit | -125.00M | 90.00M | -100.00M | 141.00M | 162.00M | 213.00M |
| EBITDA | -116.00M | -860.00M | -220.00M | -21.00M | -359.00M | -69.00M |
| Net Income | -392.00M | -895.00M | -462.00M | -264.00M | -370.00M | -376.00M |
Balance Sheet | ||||||
| Total Assets | 4.38B | 3.24B | 4.79B | 6.30B | 6.26B | 6.17B |
| Cash, Cash Equivalents and Short-Term Investments | 298.00M | 207.00M | 466.00M | 602.00M | 717.00M | 786.00M |
| Total Debt | 558.00M | 2.30B | 2.74B | 2.34B | 3.01B | 2.76B |
| Total Liabilities | 2.74B | 2.50B | 2.97B | 3.73B | 3.44B | 3.15B |
| Stockholders Equity | 798.00M | 12.00M | 921.00M | 1.55B | 2.00B | 2.38B |
Cash Flow | ||||||
| Free Cash Flow | -80.00M | 15.00M | -48.00M | 175.00M | 259.00M | 164.00M |
| Operating Cash Flow | -73.00M | 17.00M | -37.00M | 222.00M | 316.00M | 179.00M |
| Investing Cash Flow | 357.00M | 337.00M | 472.00M | -120.00M | -441.00M | -10.00M |
| Financing Cash Flow | -53.00M | -587.00M | 117.00M | -98.00M | 126.00M | -375.00M |
Aceso Life Science Group Limited Technical Analysis
Aceso Life Science Group Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | 235.60M | -13.62 | 0.00% | 3.95% | 7.98% | -236.14% | |
55 Neutral | 1.15B | 29.17 | 2.70% | 1.43% | -54.92% | 26.32% | |
54 Neutral | 193.07M | 20.74 | 0.00% | ― | -9.32% | 0.00% | |
48 Neutral | HK$280.51M | ― | -191.85% | ― | -21.03% | -97.01% | |
48 Neutral | 188.36M | -3.31 | 0.00% | ― | 7.36% | -70.59% | |
47 Neutral | 195.39M | 13.23 | -22.87% | ― | 9.69% | -33.79% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
Aceso Life Science Group Limited Corporate Events
Aceso Life Science Group Limited announced the amendment and restatement of its 2018 Facility Agreement, securing a new loan of approximately GBP87.3 million to refinance existing debt and fund capital expenditures for a property in Central London. The company plans to invest GBP17.0 million in refurbishing the UK Property to enhance tenant experience and increase rental value, amid a recovering London office market. The strategy includes energy-saving improvements and tenant area refurbishments, with a focus on securing long-term leases and increasing rental income.
Aceso Life Science Group Limited announced that all ordinary resolutions proposed at its Annual General Meeting on September 16, 2025, were approved by shareholders. This includes the re-election of directors, the re-appointment of Moore CPA Limited as auditors, and granting the board mandates to issue and repurchase shares. The unanimous approval of these resolutions reflects strong shareholder support and positions the company for continued strategic governance and operational flexibility.
Aceso Life Science Group Limited has released a supplemental announcement regarding its annual report for the year ended 31 March 2025. The auditors issued a Disclaimer of Opinion due to insufficient documentary evidence supporting the company’s cash flow forecasts and the feasibility of its asset realization plans. Despite this, the management maintains confidence in the company’s ability to continue as a going concern, supported by ongoing negotiations for refinancing loans and the Audit Committee’s concurrence with management’s assessment. The Corporate Governance Report will include details of the auditor’s modified opinions and their impact on the company’s financial position.
Aceso Life Science Group Limited has announced a further delay in the dispatch of a circular related to a major transaction. The company received a waiver from the Stock Exchange, allowing it to delay the dispatch until August 31, 2025, due to the need for additional time to incorporate necessary financial information. This delay could impact the company’s compliance with listing rules and its communication with stakeholders.
Aceso Life Science Group Limited has announced a further delay in the dispatch of a circular related to a major transaction. The company has applied for a second waiver from the Hong Kong Stock Exchange to extend the dispatch date to on or before August 31, 2025, due to the need for additional time to incorporate necessary financial information. This delay may impact stakeholders’ expectations regarding the company’s compliance with listing regulations.
Aceso Life Science Group Limited has received a waiver from the Hong Kong Stock Exchange, allowing them more time to dispatch a circular related to a major transaction announced on 15 July 2025. The waiver extends the deadline to 26 August 2025, providing the company additional time to include necessary financial statements, which could impact its compliance and operational timelines.
Aceso Life Science Group Limited has announced its upcoming Annual General Meeting (AGM) scheduled for September 16, 2025, in Hong Kong. The meeting will address several key resolutions, including the re-election of directors, the re-appointment of auditors, and the authorization for directors to manage share allotments. These decisions are crucial for the company’s governance and operational strategies, potentially impacting its market positioning and stakeholder interests.
Aceso Life Science Group Limited announced the disposal of 568,984,000 shares of HTICI on the open market, amounting to approximately HK$132,000,000. This transaction, classified as a major transaction under the Listing Rules, represents about 7.35% of HTICI’s total issued share capital and was completed at the prevailing market price.
Aceso Life Science Group Limited announced a forced sale of 1,385,116,000 shares in Hao Tian International Construction Investment Group Limited due to a loan default. This sale reduced Aceso’s shareholding in HTICI from 28.16% to 10.27%, impacting its investment portfolio and potentially affecting stakeholder interests.
Aceso Life Science Group Limited announced a non-legally binding term sheet for the potential refinancing of its 2018 Facility Agreement. The refinancing aims to address outstanding amounts and support additional capital investments in the company’s commercial properties. While negotiations continue, the outcome remains uncertain, and stakeholders are advised to exercise caution.